KR930005620A - Cataract Treatment Composition - Google Patents

Cataract Treatment Composition Download PDF

Info

Publication number
KR930005620A
KR930005620A KR1019910015670A KR910015670A KR930005620A KR 930005620 A KR930005620 A KR 930005620A KR 1019910015670 A KR1019910015670 A KR 1019910015670A KR 910015670 A KR910015670 A KR 910015670A KR 930005620 A KR930005620 A KR 930005620A
Authority
KR
South Korea
Prior art keywords
treatment composition
composition
cataract treatment
cataract
eye
Prior art date
Application number
KR1019910015670A
Other languages
Korean (ko)
Other versions
KR930011995B1 (en
Inventor
부용출
박수남
Original Assignee
한동근
태평양화학 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한동근, 태평양화학 주식회사 filed Critical 한동근
Priority to KR1019910015670A priority Critical patent/KR930011995B1/en
Publication of KR930005620A publication Critical patent/KR930005620A/en
Application granted granted Critical
Publication of KR930011995B1 publication Critical patent/KR930011995B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom

Abstract

본 발명은 눈의 수정체가 혼탁해지는 눈의 질환인 백내장(cataract)의 치료용 조성물에 관한 것으로, 특히 플라보노이드 성분의 일종인 갈랑긴을 0.01~20(w/w)% 함유한 백내장의 치료용 조성물에 관한 것이다.The present invention relates to a composition for treating cataract, a disease of the eye in which the lens of the eye becomes cloudy, and in particular, a composition for treating cataracts containing 0.01-20 (w / w)% of galangin, which is a kind of flavonoid component. It is about.

Description

백내장 치료용 조성물Cataract Treatment Composition

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (2)

갈랑긴(galangin)을 유효성분으로 함유함을 특징으로 하는 백내장 치료용 조성물.A composition for treating cataracts, comprising galangin as an active ingredient. 제1항에 있어서, 유효성분의 함량은 0.01~20.0(w/w)%임을 특징으로 하는 백내장 치료용 조성물.The composition of claim 1, wherein the content of the active ingredient is 0.01-20.0 (w / w)%. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019910015670A 1991-09-09 1991-09-09 Composition for treatment of cataract KR930011995B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019910015670A KR930011995B1 (en) 1991-09-09 1991-09-09 Composition for treatment of cataract

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019910015670A KR930011995B1 (en) 1991-09-09 1991-09-09 Composition for treatment of cataract

Publications (2)

Publication Number Publication Date
KR930005620A true KR930005620A (en) 1993-04-20
KR930011995B1 KR930011995B1 (en) 1993-12-23

Family

ID=19319718

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910015670A KR930011995B1 (en) 1991-09-09 1991-09-09 Composition for treatment of cataract

Country Status (1)

Country Link
KR (1) KR930011995B1 (en)

Also Published As

Publication number Publication date
KR930011995B1 (en) 1993-12-23

Similar Documents

Publication Publication Date Title
KR920019342A (en) Bone Disease Treatment
KR950007856A (en) Rapamycin formulations for oral administration
KR910004187A (en) Treatment of Early Ejaculation with Cetralline
FR2702391B1 (en) New multiple emulsions, their preparation, their application to the preparation of cosmetic compositions and these cosmetic compositions.
KR940007002A (en) (S)-(+)-hydroxy chloroquine
KR910000104A (en) Transparent composition
KR890015742A (en) Topical preparations for the treatment of diseases
KR940005269A (en) Vitamin E eye drops
ATE123799T1 (en) FISH OIL STABILIZATION.
ATE111736T1 (en) OCULAR HYPOTENSIVE REMEDIES.
KR910019632A (en) Pharmaceutical composition for inhibiting the development of cataracts containing a bis (alkyl-substituted-4-hydroxyphenylthio) alkane analog as an active ingredient
KR927003525A (en) Sulfonanilide Derivatives and Medicines
KR930005620A (en) Cataract Treatment Composition
ATE329570T1 (en) EMULSION CONTAINING SILICONE OIL AND CO-SOLVENT SYSTEM CONTAINING FAT-SOLUBLE COSMETIC ACTIVE INGREDIENTS AND COSMETIC PREPARATIONS PRODUCED THEREOF
KR920021128A (en) Skin cosmetic composition
KR880003211A (en) How to Treat Contact Lenses
DE69114922T2 (en) Polysulfide compounds and lipid peroxidation inhibitors that contain these polysulfide compounds as active ingredients.
KR910000115A (en) External preparation to inhibit melanin production
PT1100463E (en) NEW INJECTABLE FORMULATIONS CONTAINING RAMOPLANIN
KR920016021A (en) Animal development promoting or improving feed and methods
KR900012622A (en) Skin disease treatment composition
KR880009644A (en) Weak composition for treating ulcerative bowel disease
DK0826373T3 (en) Preventive remedy for postoperative astigmatism
KR920019343A (en) Composition for preventing and treating vascular disease using α-linolenic acid
KR960031473A (en) Antimicrobial agent with chitosan

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19970401

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee